Background Although osteoporosis affects women of all ages, the impact is most pronounced in frail residents in long-term care. Nevertheless, few interventional trials have been performed in this population, and few data on therapeutic alternatives are available in this cohort.
Purpose We describe the challenges and lessons learned in developing and carrying out a trial in frail long-term-care residents.
Methods The Zoledronic acid in frail Elders to STrengthen bone (ZEST) study was designed to examine the safety and efficacy of a single-dose therapy for osteoporosis in frail residents in long-term care in the Pittsburgh area. Women with osteoporosis who were 65 years of age and older and currently not on therapy were randomized in a blinded fashion to intravenous zoledronic acid or placebo. Follow-up of each participant was planned for 2 years. All participants received appropriate calcium and vitamin D supplementation.
Results Seven hundred and thirty-three contacts were made with long-term care residents of nine participating facilities. Of 252 women screened, 181 were eligible, enrolled, and randomized. Multiple barriers to research in long-term-care facilities were encountered but overcome with direct communication, information sessions, in-service trainings, and social events. Lessons learned included designing the study in a manner that avoided placing an additional burden on an already overcommitted facility staff, a two-stage consent process to separate screening from randomization, and a flexible examination schedule to accommodate residents while obtaining the necessary outcome measurements. Furthermore, a mobile unit accessible to participants containing state-of-the-art dual x-ray absorptiometry (DXA), assessment for vertebral fractures, and phlebotomy equipment allows all assessments to be performed on-site at each facility. Serious adverse events are collected from affiliated hospitals in real time with a novel electronic surveillance system.
Limitations The major limitation is selection of outcomes that can be assessed at participating facilities and do not require transport of participants to hospitals or clinics.
Conclusions Clinical research for osteoporosis can be successfully and safely performed with frail residents in long-term care facilities. Lessons learned from this study may inform future investigations among frail elderly residents of these facilities.
Get full access to this article
View all access options for this article.
References
1.
ZimmermanSIGirmanCJBuieVC. The prevalence of osteoporosis in nursing home residents. Osteoporos Int1999; 9: 151–57.
2.
KomarLNievesJCosmanF. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc1993; 41: 1057–64.
3.
SimonenOMikkolaT. Senile osteoporosis and femoral neck fractures in long-stay institutions. Calcif Tissue Int1991; 49(Suppl): S78–S79.
4.
FisherESBaronJAMalenkaDJ. Hip fracture incidence and mortality in New England. Epidemiology1991; 2: 116–22.
5.
Anonymous. NIH consensus declares osteoporosis a major public health issue. Osteoporos Rep2000; 16(1): 1.
6.
BlackDMCummingsSRKarpfDB. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet1996; 348: 1535–41.
7.
ChesnutCHIIISilvermanSAndrianoK. A randomized trial of nasal salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med2000; 109: 267–76.
8.
HarrisSTWattsNBGenantHK. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA1999; 282: 1344–52.
9.
EttingerBBlackDMMitlakBH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA1999; 282: 637–45.
10.
BoonenSKlemesABZhouXLindsayR. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: A pooled analysis of four studies. JAGS2010; 58: 658–63.
11.
BoonenSBlackDMColon-EmericCS. Efficacy and safety of a once-yearly intravenous zoledronic acid 5mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc2010; 58: 292–9.
12.
BoonenSMarinFMellstromD. Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc2006; 54: 782–9.
13.
GreenspanSLSchneiderDLMcClungMR. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: A randomized, double-blind, placebo-controlled trial. Ann Intern Med2002; 136: 742–6.
14.
WysowskiDKChangJT. Alendronate and risedronate: Reports of severe bone, joint, and muscle pain. Arch Intern Med2005; 165: 346–7.
15.
U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD, 2004.
16.
ReidIRBrownJPBurckhardtP. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med2002; 346: 653–61.
17.
TrevisanCBigoniMCherubiniR. Dual x-ray absorptiometry for the evaluation of bone density from the proximal femur after total hip arthroplasty: Analysis protocols and reproducibility. Calcif Tissue Int1993; 53: 158–61.
18.
McClungMRGeusensPMillerPD. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med2001; 344: 333–40.
19.
Dawson-HughesBJacquesPShippC. Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr1987; 46: 685–7.
20.
National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Excerpta Medica, Belle Mead, NJ, 2003.
21.
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Food and Nutrition Board Institute of Medicine. DRI Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. National Academy Press, Washington, DC, 1997.
22.
Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Food and Nutrition Board. DRI Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press, Washington, DC, 2011.
23.
RosenCJKhoslaS. Placebo-controlled trials in osteoporosis-proceeding with caution. N Engl J Med2010; 363(14): 1365–70.
24.
Colon-EmericCSLylesKWHouseP. Randomized trial to improve fracture prevention in nursing home residents. Am J Med2007; 120: 886–92.
25.
CrillyRGHillierLMMasonMGutmanisICoxL. Prevention of hip fractures in long-term care: Relevance of community-derived data. J Am Geriatr Soc2010; 58: 738–45.
26.
VarneyLFParkerRAVinceletteAGreenspanSL. Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom1999; 2: 275–83.
27.
GreenspanSLMaitland-RamseyLMyersE. Classification of osteoporosis in the elderly is dependent on site-specific analysis. Calcif Tissue Int1996; 58: 409–14.
28.
HolickMFSirisESBinkleyN. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab2005; 90: 3215–24.
29.
YountRJVriesJKCouncillCD. The medical archival system: An information retrieval system based on distributed parallel processing. Inform Process Manag1991; 27(4): 379–89.
